


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


### Listing of Claims:

1. (Currently amended) A compound for modulating kinase activity of Formula I,



or a pharmaceutically acceptable salt thereof, wherein,


Ar is selected from the following formulae




wherein Ar is substituted with -X and -Y-L-Z, in an ortho relationship to each other, and said five- to six-membered aromatic ring system Ar is optionally substituted with up to four  $R^1$ ;

each  $R^1$  is independently selected from -H, halogen, -CN, -NO<sub>2</sub>, -OR<sup>3</sup>, -N(R<sup>3</sup>)R<sup>3</sup>, -S(O)<sub>0-2</sub>R<sup>3</sup>, -SO<sub>2</sub>N(R<sup>3</sup>)R<sup>3</sup>, -CO<sub>2</sub>R<sup>3</sup>, -C(O)N(R<sup>3</sup>)R<sup>3</sup>, -N(R<sup>3</sup>)SO<sub>2</sub>R<sup>3</sup>, -N(R<sup>3</sup>)C(O)R<sup>3</sup>, -N(R<sup>3</sup>)CO<sub>2</sub>R<sup>3</sup>, -C(O)R<sup>3</sup>, -OC(O)R<sup>3</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

~~X is selected from the following six formulae:~~






wherein;

W is selected from  $-C(R^2)(R^3)-$ ,  $-N(R^4)-$ ,  $-S(O)_{0-2}-$ , and  $-O-$ ;

X is selected from the following formulae.



wherein  $R^{4a}$  is  $-C(O)N(R^3)R^3$ ;

$n = 1$  or  $2$ ;

$p = 0$  or  $1$ ;

$q$  is  $1$  to  $3$ ;

M is  $-OR^3$  or  $-N(R^3)R^4$ ;

each  $R^2$  is independently selected from  $-H$ , halogen, oxo,  $-CN$ ,  $-NH_2$ ,  $-NO_2$ ,  $-OR^3$ ,  $-N(R^3)R^3$ ,  $-N(R^3)R^5$ ,  $-S(O)_{0-2}R^3$ ,  $-SO_2N(R^3)R^3$ ,  $-CO_2R^3$ ,  $-C(O)N(R^3)R^3$ ,  $-N(R^3)SO_2R^3$ ,  $-N(R^3)C(O)R^3$ ,  $-N(R^3)CO_2R^3$ ,  $-N(R^3)C(O)N(R^3)R^3$ ,  $-C(O)R^3$ ,  $-OC(O)R^3$ , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

two of  $R^2$ , together with the atoms to which they are attached, can form an optionally substituted three- to seven-membered ring system;


each  $R^3$  is independently selected from  $-H$ , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

two of  $R^3$ , when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally

substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;

each  $R^4$  is independently selected from  $R^3$ ,  $-SO_2R^3$ ,  $-SO_2N(R^3)R^3$ ,  $-CO_2R^3$ ,  $-C(O)N(R^3)R^3$ , and  $-C(O)R^3$ ;

-Y-L-Z is selected from the following formulae,



wherein  $g$  is zero to two;  $D$  is selected from  $-C(R^5)(R^5)$ -,  $-O$ -,  $-S(O)_{0-2}$ -, and  $-N(R^4)$ -;  $Q$  is  $=N$ - or  $-C(R^5)$ -,  $T$  is selected from absent,  $-N(R^3)$ -,  $-S$ - and  $-O$ -; and each methylene between  $Y$  and  $T$  is optionally substituted; provided that when both  $Y$  and  $T$  are heteroatoms then  $g$  must be two;




$Y$  is selected from  $-CH_2$ -,  $-O$ -,  $-S(O)_{0-2}$ -,  $-N(R^3)$ -, and absent;

$R^5$  is selected from  $-H$ , halogen,  $-CN$ ,  $-NO_2$ ,  $-OR^3$ ,  $-N(R^3)R^4$ ,  $-S(O)_{0-2}R^3$ ,  $-SO_2N(R^3)R^3$ ,  $-CO_2R^3$ ,  $-C(O)N(R^3)R^3$ ,  $-N(R^3)SO_2R^3$ ,  $-N(R^3)C(O)R^3$ ,  $-N(R^3)CO_2R^3$ ,  $-C(O)R^3$ , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

optionally two of  $R^5$ , together with the atoms to which they are attached, form a second ring system fused with said five- to seven-membered ring system, said second ring system substituted with zero to four of  $R^5$ .



- (Canceled)
- (Canceled)
- (Canceled)

5. (currently amended) The compound according to claim 4 1, wherein Y is -O- or optionally substituted -CH<sub>2</sub>-.
6. (Canceled)
7. (Canceled)
8. (original) The compound according to claim 7 1, wherein each R<sup>2</sup> is independently selected from -H or optionally substituted lower alkyl.
9. (original) The compound according to claim 8, wherein each R<sup>2</sup> is independently selected from -H, haloalkyl, -C<sub>1-6</sub>alkyl-N(R<sup>3</sup>)R<sup>3</sup>, -C<sub>1-6</sub>alkyl-OR<sup>3</sup>, -C<sub>1-6</sub>alkyl-CO<sub>2</sub>R<sup>3</sup>, and -C<sub>1-6</sub>alkyl-C(O)N(R<sup>3</sup>)R<sup>3</sup>.<sup>8</sup>
10. (Canceled)
11. (currently amended) The compound according to claim 2 ~~40~~, wherein -Y-L-Z is selected from the following formulae,




wherein Y, T, and g are as described above.

12. (original) The compound according to claim 11, wherein g is one or two.
13. (original) The compound according to claim 12, wherein each R<sup>5</sup> is independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>3</sup>, -N(R<sup>3</sup>)R<sup>4</sup>, -S(O)<sub>0-2</sub>R<sup>3</sup>, -SO<sub>2</sub>N(R<sup>3</sup>)R<sup>3</sup>, -CO<sub>2</sub>R<sup>3</sup>, -C(O)N(R<sup>3</sup>)R<sup>3</sup>, -N(R<sup>3</sup>)SO<sub>2</sub>R<sup>3</sup>, -N(R<sup>3</sup>)C(O)R<sup>3</sup>, -N(R<sup>3</sup>)CO<sub>2</sub>R<sup>3</sup>, -C(O)R<sup>3</sup>, and optionally substituted lower alkyl.
14. (original) The compound according to claim 13, wherein -Y-L-Z is selected from the following formulae.



15. (currently amended) The compound according to claim 14, having formula **III**,



**III**

wherein J is N or CH, and B is =N- or =C(R⁵)-.

16. (original) The compound according to claim 15, wherein R<sup>3a</sup> is selected from optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl.
17. (original) The compound according to claim 16, wherein R<sup>3a</sup> is selected from optionally substituted aryl and optionally substituted heteroaryl.
18. (original) The compound according to claim 17, wherein R<sup>3a</sup> is optionally substituted phenyl.
19. (original) The compound according to claim 18, wherein said optionally substituted phenyl is substituted with at least one of halogen, -CN, -CF<sub>3</sub>, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>3</sup>, -N(R<sup>3</sup>)R<sup>3</sup>, -S(O)<sub>0-2</sub>R<sup>3</sup>, -SO<sub>2</sub>N(R<sup>3</sup>)R<sup>3</sup>, -CO<sub>2</sub>R<sup>3</sup>, -C(O)N(R<sup>3</sup>)R<sup>3</sup>, -N(R<sup>3</sup>)SO<sub>2</sub>R<sup>3</sup>, -N(R<sup>3</sup>)C(O)R<sup>3</sup>, -N(R<sup>3</sup>)CO<sub>2</sub>R<sup>3</sup>, -C(O)R<sup>3</sup>, optionally substituted lower alkyl, and optionally substituted aryl.
20. (original) The compound according to claim 19, wherein said optionally substituted phenyl group is substituted with at least one trifluoromethyl group.


21. (original) The compound according to claim 20, wherein said optionally substituted phenyl group is substituted with at least two trifluoromethyl groups
22. (original) The compound according to claim 19, wherein said optionally substituted phenyl group is substituted with at least one lower alkyl group.
23. (original) The compound according to claim 19, wherein  $R^{3b}$  is -H.
24. (original) The compound according to claim 23, wherein  $R^{4b}$  is selected from  $R^3$ , -H,  $-\text{CO}_2R^3$ ,  $-\text{C}(\text{O})\text{N}(\text{R}^3)\text{R}^4$ , and  $-\text{C}(\text{O})\text{R}^3$ .
25. (Canceled)
26. (Canceled)
27. (original) The compound according to claim 24, wherein Ar is according to the formula below.



28. (original) The compound according to claim 24, wherein Ar is according to the formula below.




29. (Canceled)
30. (Currently amended) A compound for modulating kinase activity of Formula IV,



IV

or a pharmaceutically acceptable salt thereof, wherein,

Ar is selected from the following formulae:



each R<sup>1</sup> is independently selected from -H, halogen, -CN, -NO<sub>2</sub>, -OR<sup>3</sup>, -N(R<sup>3</sup>)R<sup>3</sup>, -S(O)<sub>0-2</sub>R<sup>3</sup>, -SO<sub>2</sub>N(R<sup>3</sup>)R<sup>3</sup>, -CO<sub>2</sub>R<sup>3</sup>, -C(O)N(R<sup>3</sup>)R<sup>3</sup>, -N(R<sup>3</sup>)SO<sub>2</sub>R<sup>3</sup>, -N(R<sup>3</sup>)C(O)R<sup>3</sup>, -N(R<sup>3</sup>)CO<sub>2</sub>R<sup>3</sup>, -C(O)R<sup>3</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

optionally two of R<sup>1</sup>, together with the atoms to which they are attached, form a first ring system fused with Ar, said first ring system substituted with zero to three additional of R<sup>1</sup>;

each R<sup>2</sup> is independently selected from -H, halogen, oxo, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>3</sup>, -N(R<sup>3</sup>)R<sup>3</sup>, -N(R<sup>3</sup>)R<sup>5</sup>, -S(O)<sub>0-2</sub>R<sup>3</sup>, -SO<sub>2</sub>N(R<sup>3</sup>)R<sup>3</sup>, -CO<sub>2</sub>R<sup>3</sup>, -C(O)N(R<sup>3</sup>)R<sup>3</sup>, -N(R<sup>3</sup>)SO<sub>2</sub>R<sup>3</sup>, -N(R<sup>3</sup>)C(O)R<sup>3</sup>, -N(R<sup>3</sup>)CO<sub>2</sub>R<sup>3</sup>, -N(R<sup>3</sup>)C(O)N(R<sup>3</sup>)R<sup>3</sup>, -C(O)R<sup>3</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

two of R<sup>2</sup>, together with the atoms to which they are attached, can form an optionally substituted three- to seven-membered ring system;

each R<sup>3</sup> is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

two of  $R^3$ , when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;

each  $R^4$  is independently selected from  $R^3$ ,  $-SO_2R^3$ ,  $-SO_2N(R^3)R^3$ ,  $-CO_2R^3$ ,  $-C(O)N(R^3)R^3$ , and  $-C(O)R^3$ ;

Y is selected from optionally substituted  $-CH_2-$ ,  $-O-$ ,  $-S-$ , and  $-N(R^3)-$ ;

L is selected from optionally substituted  $-CH_2-$ ,  $-O-$ ,  $-S-$ ,  $-N(R^3)-$  and absent;

provided that Y and L are not both heteroatoms;

B is  $=N-$  or  $=C(H)-$ ;

at each instance,  $R^5$  and  $R^6$  are independently selected from  $-H$ , halogen,  $-CN$ ,  $-NO_2$ ,  $-OR^3$ ,  $-N(R^3)R^4$ ,  $-S(O)_{0-2}R^3$ ,  $-SO_2N(R^3)R^3$ ,  $-CO_2R^3$ ,  $-C(O)N(R^3)R^3$ ,  $-N(R^3)SO_2R^3$ ,  $-N(R^3)C(O)R^3$ ,  $-N(R^3)CO_2R^3$ ,  $-C(O)R^3$ , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

optionally two of  $R^5$ , together with the atoms to which they are attached, form a ring system fused with the ring containing B according to formula **IV**, said ring system substituted with zero to two additional of  $R^5$ .

31. (original) The compound according to claim 30, wherein Y is  $-O-$  and L is optionally substituted  $-CH_2-$ .
32. (original) The compound according to claim 31, wherein at least one of  $R^6$  is optionally substituted lower alkyl.
33. (original) The compound according to claim 32, wherein said at least one optionally substituted lower alkyl is *meta*- to the piperazine urea function as depicted in formula **IV**.
34. (original) The compound according to claim 33, wherein  $R^{4a}$  is selected from  $R^3$ ,  $-H$ ,  $-CO_2R^3$ ,  $-C(O)N(R^3)R^4$ , and  $-C(O)R^3$ .



35. (original) The compound according to claim 34, wherein  $R^{4a}$  is selected from -H,  $-CO_2R^3$ ,  $-C(O)N(R^3)R^4$ , and  $-C(O)R^3$ .
36. (original) The compound according to claim 35, wherein -Y-L- is  $-OCH_2-$ .
37. (Canceled)
38. (Canceled)
39. (original) The compound according to claim 36, wherein Ar is according to the formula below.



40. (original) The compound according to claim 36, wherein Ar is according to the formula below.



41. (Cancelled)
42. ~~The compound according to claim 1.~~ A compounds selected from Table 4.

**Table 4**

97	N-[3,5-bis(trifluoromethyl)phenyl]-4-{3-[(pyridin-4-ylmethyl)oxy]pyridin-2-yl}piperazine-1-carboxamide	
103	N-(4-chlorophenyl)-4-{3-[(pyridin-4-ylmethyl)oxy]pyridin-2-yl}piperazine-1-carboxamide	

**Table 4**

105	N-(3-chlorophenyl)-4-{3-[(pyridin-4-ylmethyl)oxy]pyridin-2-yl}piperazine-1-carboxamide	
142	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide	
144	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	
161	methyl [4-({2-[4-({(3-ethylphenyl)amino)carbonyl}piperazin-1-yl)pyridin-3-yl]oxy}methyl)pyridin-2-yl]carbamate	
164	methyl [4-({2-[4-({(3-bromophenyl)amino)carbonyl}piperazin-1-yl)pyridin-3-yl]oxy}methyl)pyridin-2-yl]carbamate	
165	methyl [4-({2-[4-({(3-methoxyphenyl)amino)carbonyl}piperazin-1-yl)pyridin-3-yl]oxy}methyl)pyridin-2-yl]carbamate	

**Table 4**

166	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-(methyloxy)phenyl]piperazine-1-carboxamide	
167	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-(1-methylethyl)phenyl]piperazine-1-carboxamide	
168	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-[(trifluoromethyl)oxy]phenyl]piperazine-1-carboxamide	
169	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[2-fluoro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	
170	N-(3-ethylphenyl)-4-[3-({[2-({[3-(3-ethylphenyl)amino]carbonyl}amino)pyridin-4-yl]methyl}oxy)pyridin-2-yl]piperazine-1-carboxamide	

**Table 4**

171	N-(3-ethylphenyl)-4-(3-{{[(2-{{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl]oxy}pyridin-2-yl]piperazine-1-carboxamide	
173	N-[3,5-bis(trifluoromethyl)phenyl]-4-(3-{{[(2-{{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl]oxy}pyridin-2-yl]piperazine-1-carboxamide	
174	4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3-(trifluoromethyl)phenyl]piperazine-1-carboxamide	
175	4-[3-{{[(2-(acetylamino)pyridin-4-yl)methyl]oxy}pyridin-2-yl]-N-(3-ethylphenyl)piperazine-1-carboxamide	
176	4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-ethyl-4-fluorophenyl)piperazine-1-carboxamide	

**Table 4**

177	2-[4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)piperazin-1-yl]-N-[3,5-bis(trifluoromethyl)phenyl]acetamide	
178	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-phenylpiperazine-1-carboxamide	
179	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3-chloro-5-ethylphenyl)piperazine-1-carboxamide	
180	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(5-ethyl-2-fluorophenyl)piperazine-1-carboxamide	
181	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3-bromo-5-ethylphenyl)piperazine-1-carboxamide	

Table 4

182	2-(4-methylpiperazin-1-yl)ethyl [4-({(3-ethylphenyl)amino}carbonyl)piperazin-1-yl]pyridin-3-yl]oxy;methyl]pyridin-2-yl]carbamate	
183	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy;pyridin-2-yl)-N-(3-chlorophenyl)piperazine-1-carboxamide	
184	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy;pyridin-2-yl)-N-(3-bromophenyl)piperazine-1-carboxamide	
185	N-[4-({(2-(4-acetyl)piperazin-1-yl)pyridin-3-yl]oxy;methyl]pyridin-2-yl]-2-(4-methylpiperazin-1-yl)acetamide	
186	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy;pyridin-2-yl)-N-(3-fluorophenyl)piperazine-1-carboxamide	
187	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy;pyridin-2-yl)-N-(4-fluorophenyl)piperazine-1-carboxamide	

**Table 4**

188	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(2-fluorophenyl)piperazine-1-carboxamide	
189	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3,5-diethylphenyl)piperazine-1-carboxamide	
190	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}5-bromopyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	
191	N-methyl-4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide	
192	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[2-chloro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	
193	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(5-chloro-2-fluorophenyl)piperazine-1-carboxamide	
194	4-(3-{{(2-amino-5-bromopyrimidin-4-yl)methyl}oxy}5-bromopyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	

**Table 4**

195	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[2-fluoro-3-(trifluoromethyl)phenyl]piperazine-1-carboxamide	
196	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	
197	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3,5-dichlorophenyl)piperazine-1-carboxamide	
198	N-(3-chloro-5-ethylphenyl)-4-(3-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide	
199	N-(5-ethyl-2-fluorophenyl)-4-(3-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide	



**Table 4**

200	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-ethyl-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	
204	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-methylpiperazine-1-carboxamide	
205	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-ethylpiperazine-1-carboxamide	
206	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-cyclohexylpiperazine-1-carboxamide	
207	4-({[2-(4-acetyl)piperazin-1-yl]pyridin-3-yl}oxy)methylpyrimidin-2-amine	
208	4-({[2-(4-propanoyl)piperazin-1-yl]pyridin-3-yl}oxy)methylpyrimidin-2-amine	
209	N-(3-cyclopropylphenyl)-4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide	

**Table 4**

210	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3-cyclopropylphenyl)piperazine-1-carboxamide	
211	N-[2-fluoro-5-(trifluoromethyl)phenyl]-4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide	
212	N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide	
213	N-(3,5-dichlorophenyl)-4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide	
214	4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-(trifluoromethyl)phenyl]piperazine-1-carboxamide	

**Table 4**

216	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide	
219	4-[[{2-[4-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)piperazin-1-yl]pyridin-3-yl]oxy)methyl]pyrimidin-2-amine	
220	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(2-methylpropyl)piperazine-1-carboxamide	
226	N-(3,5-diethylphenyl)-4-(3-{[(2-{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl]oxy)methyl]pyridin-2-yl}piperazine-1-carboxamide	
227	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-methylpyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	
228	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-methylpyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide	

**Table 4**

233	N-[3-chloro-5-(trifluoromethyl)phenyl]-4-(3-{{(2-{{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide	
235	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-chloro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	
237	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}-6-chloropyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	
243	N-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-4-(3-{{(2-{{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide	
244	4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}-6-chloropyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide	

**Table 4**

245	4-(3-{{1-(2-aminopyrimidin-4-yl)ethyl}oxy}pyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	
246	4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-chloropyridin-2-yl)-N-(5-ethyl-2-fluorophenyl)piperazine-1-carboxamide	
247	4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-ethyl-5-fluorophenyl)piperazine-1-carboxamide	
249	4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	
250	4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]-N-methylpiperazine-1-carboxamide	

43. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
44. (Canceled).
45. (Canceled)
46. (Canceled)
47. (Canceled)

- 48. (Canceled)
- 49. (Canceled)
- 50. (Canceled).
- 51. (Canceled)
- 52. (Canceled)
- 53. (Canceled)
- 54. (Canceled)
- 55. (Canceled)
- 56. (Canceled)
- 57. (Canceled)